Multi User License - $2,999
Due to its significance for human health and social significance, the manufacturing of medicines is a strategic sector.
This industry began in Egypt with Tal ‘at Harp and the establishment of the first Egyptian pharmaceutical company in 1939 under the name of “Misr Company for Pharmaceuticals” believing in the strategic importance of a strong national pharmaceutical industry.
Every year, billions of dollars are invested in research and development worldwide to support this industry, which aims to increase human ability to face various types of diseases.
This is evidently reflected in the rising life expectancy of people, especially in industrial countries where medicine production is highly concentrated.
Egypt has undergone numerous changes throughout its history and witnessed a wide range of key market players, attracting a large number of investments into the expanding industry, which accounts for approximately 30% of the supply of pharmaceuticals in the MENA market.
The Egypt Pharmaceutical Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
The first fixed dose combination triple therapy in one device for asthma has been introduced in Egypt by Novartis Pharma S.A.E. (Novartis Egypt). The goal is to give patients better control over their condition and improve their quality of life.
The patient journey in Egypt, advancements in therapies for uncontrolled asthma, and the advantages of modern inhalers in promoting greater treatment adherence were brought up for discussion by well-known specialists in respiratory and pulmonology.
The world’s most common chronic respiratory disease, asthma has a significant negative impact on patients’ health and finances. Asthma affected millions of people worldwide, resulting in deaths.
The principal fixed portion blend triple treatment in one gadget in Egypt is exceptionally sure information for patients.With 19% improvement for dual therapy and 43% improvement for triple therapy, these new products have demonstrated their capacity to significantly improve quality of life and reduce exacerbations in comparison to the standard of care.
New inhalers with new molecules have been introduced into the Egyptian market for both dual therapy and triple therapy inhalers with superior control, mometasone furoate has demonstrated the highest binding affinity.
Novartis strives to develop treatments for both common and uncommon diseases.”For a very long time, Novartis has placed a high priority on treating respiratory conditions, particularly asthma, which has such a high prevalence rate.
As a leading respiratory company, Novartis take the responsibilities to improve the lives of people all over the world who suffer from lung conditions very seriously.
Head of Immunology, Dermatology, and Respiratory Franchise at Novartis Egypt, stated, “Novartis hopes to solve the unmet needs in asthma management, improve treatment outcomes for asthma and other respiratory diseases, and relieve the burden such conditions place on the healthcare sector and society as a whole by prioritising innovation and establishing close partnerships with patients and medical experts.”
© Copyright 2017-2022. Mobility Foresights. All Rights Reserved.